{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"15","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Number of treatment cycles completed by study participants.","dispersionType":"Full Range","groups":[{"description":"Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)","id":"OG000","title":"Tivantinib Treatment"}],"paramType":"MEAN","populationDescription":"No participants responded to the therapy and no analyses were done","reportingStatus":"POSTED","timeFrame":"From start of participant treatment to completion or disease progression; assessed up to 16 months","title":"Cycles of Tivantinib Treatment Administered","type":"POST_HOC","unitOfMeasure":"number of treatment cycles"}